Vis enkel innførsel

dc.contributor.authorRifat, Mahfuzaen_US
dc.contributor.authorHall, Johnen_US
dc.contributor.authorOldmeadow, Christopheren_US
dc.contributor.authorHusain, Ashaqueen_US
dc.contributor.authorHinderaker, Sven Gudmunden_US
dc.contributor.authorMilton, Abul Hasnaten_US
dc.date.accessioned2016-05-26T11:06:14Z
dc.date.available2016-05-26T11:06:14Z
dc.date.issued2015-09-08
dc.PublishedBMJ Open 2015, 5:e008273(9)eng
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/1956/12016
dc.description.abstractObjective. Previous tuberculosis (TB) treatment status is an established risk factor for multidrug-resistant TB (MDR-TB). This study explores which factors related to previous TB treatment may lead to the development of multidrug resistant in Bangladesh. Design. We previously conducted a large case–control study to identify risk factors for developing MDR-TB in Bangladesh. Patients who had a history of previous TB treatment, either MDR-TB or non-MDR-TB, were interviewed about their previous treatment episode. This study restricts analysis to the strata of patients who have been previously treated for TB. Information was collected through face-to-face interviews and record reviews. Unadjusted and multivariable logistic regression was used for data analysis. Setting. Central-level, district-level and subdistrict-level hospitals in rural and urban Bangladesh. Results. The strata of previously treated patients include a total of 293 patients (245 current MDR-TB; 48 non-MDR-TB). Overall, 54% of patients received previous TB treatment more than once, and all of these patients were multidrug resistant. Patients with MDR-TB were more likely to have experienced the following factors: incomplete treatment (OR 4.3; 95% CI 1.7 to 10.6), adverse reactions due to TB treatment (OR 8.2; 95% CI 3.2 to 20.7), hospitalisation for symptoms associated with TB (OR 16.9; CI 1.8 to 156.2), DOTS (directly observed treatment, short-course) centre as treatment unit (OR 6.4; CI 1.8 to 22.8), supervised treatment (OR 3.8; CI 1.6 to 9.5); time-to-treatment centre (OR 0.984; CI 0.974 to 0.993). Conclusions. Incomplete treatment, hospitalisation for TB treatment and adverse reaction are the factors related to previous TB treatment of patients with MDR-TB. Although the presence of supervised treatment (DOT), less time-to-treatment centres and being treated in DOTS centres were relatively higher among the patients with MDR-TB compared with patients without MDR-TB, these findings include information of their most recent TB treatment episode only. Most (64.5%) of the patients with MDR-TB had received TB treatment more than once.en_US
dc.language.isoengeng
dc.publisherBMJ Publishing Groupeng
dc.rightsAttribution CC BY-NC 4.0eng
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0eng
dc.titleFactors related to previous tuberculosis treatment of patients with multidrugresistant tuberculosis in Bangladeshen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2016-03-08T10:45:38Z
dc.description.versionpublishedVersionen_US
dc.identifier.doihttps://doi.org/10.1136/bmjopen-2015-008273
dc.identifier.cristin1333023
dc.subject.nsiVDP::Medisinske Fag: 700en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC 4.0
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC 4.0